EMA's committee for human medicines (CHMP) has approved additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by
One site, located in Reinbek,
The two new sites are expected to support the continued supply of Comirnaty in the
This recommendation does not require a
The changes described will be included in the publicly available information on this vaccine.
Related content
Comirnaty: EPAR
Comirnaty: Paediatric investigation plan
Related content
Coronavirus disease (COVID-19)
COVID-19: latest updates
COVID-19 vaccines: authorised
COVID-19 vaccines: development, evaluation, approval and monitoring
Contact:
Tel: +31 (0)88 781 8427
Email: press@ema.europa.eu
(C) 2021 Electronic News Publishing, source